# A Study of ARRY-334543 in Patients With Advanced Cancer

> **NCT00278902** · PHASE1 · COMPLETED · sponsor: **Array Biopharma, now a wholly owned subsidiary of Pfizer** · enrollment: 96 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** ARRY-334543, EGFR/ErbB2 inhibitor; oral

## Key facts

- **NCT ID:** NCT00278902
- **Lead sponsor:** Array Biopharma, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00278902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00278902, "A Study of ARRY-334543 in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00278902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*